Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 10, 2011, Pages 7498-7505

  Loftus, Jane V ^a   Sultan, Marla B ^b   Pleil, Andreas M ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; APTAMER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION; VISION; VISUAL ACUITY; VISUAL ANALOG SCALE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETIC RETINOPATHY; HUMAN; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; RETINA MACULA EDEMA; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISION, OCULAR; VISUAL ACUITY; YOUNG ADULT;

EID: 84856386357     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7613     Document Type: Article

References (34)

1. Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health-related quality of life. Graefes Arch Clin Exp Ophthalmol. 2009;247:267-272.
2. Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92:89-92.
3. Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, Keightley S. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy. Diabet Med. 2006;23:60-66.
4. Sharma S, Oliver-Fernandez A, Liu W, Buchholz P, Walt J. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol. 2005;16:155-159.
5. Tranos PG, Topouzis F, Stangos NT, et al. Effect of laser photocoagulation treatment for diabetic macular oedema on patient's vision-related quality of life. Curr Eye Res. 2004;29:41-49.
6. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
7. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: The Singapore Malay Eye Study. Ophthalmology. 2008;115:1869-1875.
8. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82: 844-851.
9. American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2008. http:// www.aao.org/ppp. Accessed July 20, 2010.
10. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.
11. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078-1086.
12. Massin P, Mandello B, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (the RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter, phase II study. Diabetes Care. 2010;33:2399-2405.
13. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2009;116:2175-2181.
14. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, for the Macugen1013 Study Group. A phase 2/3, multicenter, randomized, doublemasked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011;118:1107-1118.
15. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
16. Spilker B, Revicki DA. Taxonomy of quality of life. In: Spilker B, ed. Quality of life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1999;25-32.
17. Finger RP, Fleckenstein M, Holz FG, et al. Quality of life in agerelated macular degeneration: a review of available vision-specific psychometric tools. Qual Life Res. 2008;17:559-574.
18. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD; National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119: 1050-1058.
19. Mangione CM. The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). http://www.nei.nih.gov/resources/ visionfunction/manual_cm2000.pdf. Accessed February 23, 2011.
20. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol. 2010;94:319-323.
21. Leys A, Zlateva G, Shah SN, et al. Quality of life in patients with age-related macular degeneration: results from the VISION study. Eye. 2008;22:792-798.
22. McKean-Cowdin R, Varma R, Hays RD, et al. Longitudinal changes in visual acuity and health-related quality of life The Los Angeles Latino Eye Study. Ophthalmology. 2010;117:1900-1907.
23. Ringsdorf L, McGwin G Jr, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma. 2006;15:414-418.
24. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572-579.
25. Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G. Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr Med Res Opin. 2008;24:2103-2111.
26. Suner IJ, Kokame GT, Yu E, et al. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50:3629-3635.
27. Langelaan M, de Boer MR, van Nispen RM, Wouters B, Moll AC, van Rens GH. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol. 2007;14:119-126.
28. Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24:1763-1770.
29. van Nispen RM, de Boer MR, Hoeijmakers JG, Ringens PJ, van Rens GH. Co-morbidity and visual acuity are risk factors for health-related quality of life decline: five-month follow-up EQ-5D data of visually impaired older patients. Health Qual Life Outcomes. 2009;7:18.
30. EuroQol Group. What is EQ-5D? http://www.euroqol.org/eq-5d/ what-is-eq-5d/how-to-use-eq-5d.html. Accessed October 1, 2010.
31. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes. 2008;6:95.
32. Nyman SR, Gosney MA, Victor CR. Psychosocial impact of visual impairment in working-age adults. Br J Ophthalmol. 2010;94: 1427-1431.
33. Aiello LP, Edwards AR, Beck RW, et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/ grid photocoagulation for diabetic macular edema. Ophthalmology. 2010;117:946-953.
34. Grandy S, Fox KM. EQ-5D visual analogue scale and utility index values in individuals with diabetes and at risk for diabetes: findings from the study to help improve early evaluation and management of risk factors leading to diabetes (SHIELD). Health Qual Life Outcomes. 2008;6:18.